Cytek Biosciences (NASDAQ:CTKB) is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.
The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters. These instruments are complemented by a range of pre-formulated antibody panels, custom reagent kits and data analysis software. Cytek’s offerings are tailored to diverse applications such as immunophenotyping, cell signaling studies, oncology research and translational medicine.
Founded in 2014 and headquartered in Fremont, California, Cytek Biosciences has established a global distribution network serving academic institutions, biopharmaceutical companies and clinical laboratories across North America, Europe and Asia. The company completed its initial public offering in mid-2021, marking a key milestone in its growth strategy. Under the leadership of Dr. Ping Wang, Cytek continues to invest in research and development to extend its spectral cytometry capabilities and broaden its product pipeline.
With a focus on advancing single-cell profiling, Cytek Biosciences aims to accelerate discoveries in immunology, cell therapy and personalized medicine. Its integrated hardware, reagents and software ecosystem provides end users with streamlined workflows, rapid assay development and robust data quality, supporting cutting-edge research and clinical investigations worldwide.
